Drug Discovery World
DECEMBER 15, 2022
As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.
XTalks
FEBRUARY 11, 2021
This has ushered in a new era of genomics that is fostering rapid, detailed and personalized insights into human genetics. Xtalks is celebrating the International Day of Women and Girls in Science with a special overview of notable female scientists who have made revolutionary contributions to the field of genetics. Rosalind Franklin.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
WCG Clinical
NOVEMBER 17, 2023
Although the NIH Guidelines were originally written with non-clinical laboratory research in mind, they also apply to human gene transfer (HGT) research, wherein rsNA or rsNA-containing products are administered to research participants. Since then, however, certain genetic engineering technologies (e.g.,
Drug Discovery World
MARCH 21, 2023
Published in Molecular Cell, the study explains the rules determining to what extent genes respond to CRISPR activation, ensuring that future research can be designed as efficiently as possible. CRISPR activation (CRISPRa) is a type of CRISPR gene editing that is used to overexpress certain genes.
Drug Discovery World
JULY 10, 2023
This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. Figure 1: Characterisation of chimeric founders for a genetically humanized allele. (A)
The Pharma Data
JANUARY 17, 2021
–( BUSINESS WIRE )– Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the six-months period ending December 31, 2020. 18, 2021 07:00 UTC. BASINGSTOKE, England & MADISON, Wis.–( and £49.0m
Drug Discovery World
APRIL 4, 2023
Read more: FDA Fast Track Designation for retinitis pigmentosa treatment Drug candidate for TUBB4a leukodystrophy, SynaptixBio The FDA has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.
Expert insights. Personalized for you.
52 
Let's personalize your content